🏢 官网IRDXCMCodex · 实盘不做把握 6/10
北京时间·🕒 发布 05:15:00时区推断·⟳ 抓取 05:16:26·⚡ 决策 07-23 05:18:29 +2m03s·96.5 天前
Dexcom入选FDA TEMPO数字健康设备试点首批参与方
Dexcom（DXCM.US）被FDA选为TEMPO试点首个参与方，方向上有助于其AI血糖健康项目和真实世界证据积累。
📄 原文DXCM↗ 原文
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Participation advances the company’s vision and regulatory pathway for earlier intervention, screening for prediabetes…
不做 Dexcom（DXCM.US）
不做：这是FDA试点参与资格和长期监管路径信号，不是正式获批、医保覆盖、订单或指引上修，未披露可量化收入增量，短线edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 low · price-in 风险 medium ↗
关键理由
- Dexcom（DXCM.US）被FDA选为TEMPO试点首个参与方，方向上有助于其AI血糖健康项目和真实世界证据积累。
- 该事件只是监管试点参与资格，不是正式获批、医保覆盖扩张、订单、销售指引或可量化商业化增量。
- 正文未披露新增收入、付费用户规模、报销路径或产品准入时间表，短线难形成相对市值足够明确的重定价边际。
主要风险
- 若后续FDA试点转化为正式监管路径、医保覆盖或大规模筛查商业化安排，需按新事件重新评估。
- 本次为公司官方IR发布，存在品牌宣传和长期路线图确认属性，短线交易催化强度不足。
原文全文
展开原文 · 3,852 字
Participation advances the company’s vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment
SAN DIEGO--(BUSINESS WIRE)--
Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence.
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Participation in the TEMPO pilot will allow Dexcom to implement an AI-powered glucose health program that integrates data from Dexcom G7 and Stelo with contextual health information such as nutrition, physical activity, sleep and stress, to deliver more personalized insights for healthcare professionals and program eligible users. The program leverages Dexcom's industry-leading clinician software platform, to provide healthcare professionals with a more comprehensive view of metabolic health, helping them monitor progress and personalize therapy at a population level. The program is also intended as an aid in the screening of prediabetes and Type 2 diabetes through integrated digital health metrics and may contribute to improving glycemic control and lowering HbA1c in people with prediabetes.
The pilot will support Dexcom's efforts to generate real-world evidence evaluating how glucose biosensing technology and AI-enabled digital health programs advance earlier intervention strategies, including research focused on prediabetes and Type 2 diabetes, and future efforts to collect evidence for broader cardiometabolic health outcomes.
“Glucose is one of the body's most powerful health signals, providing immediate insight into a person’s overall health,” said Jake Leach, president and CEO of Dexcom. “Transforming this data into more personalized, proactive screening and preventive care has the potential to help millions of people make meaningful lifestyle changes before disease develops, while also generating the evidence needed to expand access to these technologies. Being the first company selected by the FDA to participate in this pilot program marks another first for Dexcom and underscores our continued leadership in innovation."
The FDA launched the TEMPO pilot to evaluate a new regulatory approach for certain digital health technologies that support chronic disease management while collecting real-world performance data. The initiative is part of the agency's broader effort to accelerate access to innovative digital health solutions while maintaining patient safety.
Dexcom's participation builds on the company's continued investment in digital health and expanding the role of glucose biosensing across the continuum of care. The company continues to advance technologies that help people and healthcare professionals better understand the relationship between glucose and lifestyle factors to enable more personalized health decisions.
To learn more about the portfolio of Dexcom glucose biosensors, visit Dexcom.com .
About Dexcom
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit Dexcom.com .
Category: IR
Media Contact
Nadia Conard
mediarelations@dexcom.com
Investor Contact
Sean Christensen
sean.christensen@dexcom.com
Source: DexCom, Inc.
SAN DIEGO--(BUSINESS WIRE)--
Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence.
Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
Participation in the TEMPO pilot will allow Dexcom to implement an AI-powered glucose health program that integrates data from Dexcom G7 and Stelo with contextual health information such as nutrition, physical activity, sleep and stress, to deliver more personalized insights for healthcare professionals and program eligible users. The program leverages Dexcom's industry-leading clinician software platform, to provide healthcare professionals with a more comprehensive view of metabolic health, helping them monitor progress and personalize therapy at a population level. The program is also intended as an aid in the screening of prediabetes and Type 2 diabetes through integrated digital health metrics and may contribute to improving glycemic control and lowering HbA1c in people with prediabetes.
The pilot will support Dexcom's efforts to generate real-world evidence evaluating how glucose biosensing technology and AI-enabled digital health programs advance earlier intervention strategies, including research focused on prediabetes and Type 2 diabetes, and future efforts to collect evidence for broader cardiometabolic health outcomes.
“Glucose is one of the body's most powerful health signals, providing immediate insight into a person’s overall health,” said Jake Leach, president and CEO of Dexcom. “Transforming this data into more personalized, proactive screening and preventive care has the potential to help millions of people make meaningful lifestyle changes before disease develops, while also generating the evidence needed to expand access to these technologies. Being the first company selected by the FDA to participate in this pilot program marks another first for Dexcom and underscores our continued leadership in innovation."
The FDA launched the TEMPO pilot to evaluate a new regulatory approach for certain digital health technologies that support chronic disease management while collecting real-world performance data. The initiative is part of the agency's broader effort to accelerate access to innovative digital health solutions while maintaining patient safety.
Dexcom's participation builds on the company's continued investment in digital health and expanding the role of glucose biosensing across the continuum of care. The company continues to advance technologies that help people and healthcare professionals better understand the relationship between glucose and lifestyle factors to enable more personalized health decisions.
To learn more about the portfolio of Dexcom glucose biosensors, visit Dexcom.com .
About Dexcom
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit Dexcom.com .
Category: IR
Media Contact
Nadia Conard
mediarelations@dexcom.com
Investor Contact
Sean Christensen
sean.christensen@dexcom.com
Source: DexCom, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。